Related Experiment Video
Updated: Jul 5, 2026
07:43
Establishment of Zone-Enriched Primary Cultures from the Mouse Adrenal Cortex
Published on: May 8, 2026
New mechanisms to control aldosterone synthesis
H S Willenberg1, S Schinner, I Ansurudeen
1Department of Endocrinology, Diabetes and Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany. Holger.Willenberg@uniduesseldorf.de
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|May 22, 2008
Summary
Primary aldosteronism, a cause of hypertension, involves aldosterone regulation. New factors controlling aldosterone release may lead to novel therapies for hypertension and metabolic diseases.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
Background:
- Arterial hypertension is a major cardiovascular risk factor.
- Primary aldosteronism is a significant cause of secondary hypertension.
- Aldosterone regulates fluid volume and electrolyte balance, impacting hypertension severity.
Purpose of the Study:
- To review the regulation of aldosterone synthesis and release.
- To highlight novel factors influencing aldosterone production.
- To explore potential therapeutic targets for hypertension and metabolic diseases.
Main Methods:
- Literature review of aldosterone regulation.
- Analysis of classic and novel stimulators of aldosterone synthesis.
- Discussion of feedback loops in adrenal steroidogenesis.
Main Results:
- Aldosterone synthesis is controlled by the hypothalamic-pituitary-adrenal axis and the renin-angiotensin-aldosterone system.
- Classic stimulators include angiotensin, potassium, and corticotropin.
- Novel regulators identified include endothelial cell-derived factors and adipokines.
Conclusions:
- Understanding aldosterone regulation is crucial for managing hypertension.
- New factors controlling aldosterone release offer potential for novel therapeutic strategies.
- Further research into these factors could benefit treatment of hypertension and metabolic disorders.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...